Alberto Ortiz

List of Publications by Citations

661 papers	68,229 citations	84 h-index	253 g-index
770 ext. papers	87,403 ext. citations	7.2 avg, IF	7.97 L-index

#	Paper	IF	Citations
661	Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet, The* , **2015**, 385, 117-71	40	4599
660	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1789-1858	40	4524
659	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet, The*, **2015**, 386, 743-800	40	3802
658	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1545-1602	40	3801
657	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*, **2018**, 7, 1535750	16.4	3642
656	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1459-1544	40	3525
655	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1211-1259	40	3432
654	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1736-1788	40	2850
653	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1151-1210	40	2542
652	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1659-1724	40	2431
651	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1923-1994	40	1964
650	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1345-1422	40	1378
649	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1859-1922	40	1283
648	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1603-1658	40	1216
647	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet, The*, **2015**, 386, 2145-91	40	1203
646	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1260-1344	40	1152
645	Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2020**, 395, 709-733	40	1021

644	Normal and pathologic concentrations of uremic toxins. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 1258-70	12.7	578
643	Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1684-1735	40	483
642	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1084-1150	40	421
641	Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 12024-9	11.5	391
640	NF-kappaB in renal inflammation. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1254-62	12.7	385
639	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet, The*, **2018**, 391, 2236-2271	40	381
638	Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. *Molecular Genetics and Metabolism*, **2008**, 93, 112-28	3.7	375
637	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet, The*, **2017**, 390, 231-266	40	352
636	3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. *Circulation Research*, **1998**, 83, 490-500	15.7	350
635	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet, The*, **2016**, 388, 1813-1850	40	302
634	The inflammatory cytokines TWEAK and TNF reduce renal klotho expression through NFB. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1315-25	12.7	257
633	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. *Lancet, The*, **2014**, 383, 1831-43	40	250
632	Animal models of cardiovascular diseases. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 497841		226
631	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. *Lancet, The*, **2017**, 390, 1423-1459	40	224
630	Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. *JAMA Pediatrics*, **2017**, 171, 573-592	8.3	216
629	Fabry disease revisited: Management and treatment recommendations for adult patients. *Molecular Genetics and Metabolism*, **2018**, 123, 416-427	3.7	215
628	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 2091-2138	40	210
627	Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 218-229	12.7	199

626	Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet, The*, **2018**, 392, 1995-2051	40	189
625	Tenofovir nephrotoxicity: 2011 update. *AIDS Research and Treatment*, **2011**, 2011, 354908	2.3	168
624	Mechanisms of renal apoptosis in health and disease. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1634-42	12.7	168
623	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 1999-2010	12.7	164
622	Targeting the progression of chronic kidney disease. *Nature Reviews Nephrology*, **2020**, 16, 269-288	14.9	158
621	The systemic nature of CKD. *Nature Reviews Nephrology*, **2017**, 13, 344-358	14.9	152
620	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. *Nephrology Dialysis Transplantation*, **2016**, 31, 337-48	4.3	150
619	The cytokine TWEAK modulates renal tubulointerstitial inflammation. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 695-703	12.7	145
618	Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. *Apoptosis: an International Journal on Programmed Cell Death*, **2008**, 13, 11-32	5.4	143
617	Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. *Nephrology Dialysis Transplantation*, **2008**, 23, 1600-7	4.3	142
616	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *Kidney International*, **1995**, 47, 1419-25	9.9	140
615	Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. *Nephrology Dialysis Transplantation*, **2011**, 26, 1797-802	4.3	138
614	Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. *Nephrology Dialysis Transplantation*, **2011**, 26, 2567-71	4.3	135
613	Therapeutic approaches to diabetic nephropathy--beyond the RAS. *Nature Reviews Nephrology*, **2014**, 10, 325-46	14.9	131
612	Implementation of proteomic biomarkers: making it work. *European Journal of Clinical Investigation*, **2012**, 42, 1027-36	4.6	131
611	Suppressors of cytokine signaling abrogate diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 763-72	12.7	131
610	Global Cardiovascular and Renal Outcomes of Reduced GFR. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 2167-2179	12.7	127
609	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2012**, 302, F647-57	4.3	120

608	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. *Nature Reviews Nephrology*, **2012**, 8, 362-9	14.9	117
607	Cytokine cooperation in renal tubular cell injury: the role of TWEAK. *Kidney International*, **2006**, 70, 1750-8	9.9	117
606	Unilateral ureteral obstruction: beyond obstruction. *International Urology and Nephrology*, **2014**, 46, 765-76	2.5	116
605	Role of cytokines in the response to erythropoietin in hemodialysis patients. *Kidney International*, **1998**, 54, 1337-43	9.9	116
604	Paracetamol-induced renal tubular injury: a role for ER stress. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 380-9	12.7	115
603	Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 3072-80	12.7	114
602	Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. *Kidney International*, **2000**, 57, 969-81	9.9	113
601	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. *Nephrology Dialysis Transplantation*, **2021**, 36, 87-94	4.3	109
600	The double challenge of resistant hypertension and chronic kidney disease. *Lancet, The*, **2015**, 386, 1588-98	45	108
599	Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 916-22	9.4	107
598	Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. *Nephrology Dialysis Transplantation*, **2012**, 27, 1042-9	4.3	106
597	Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. *Kidney International*, **2014**, 85, 103-11	9.9	102
596	Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. *Journal of Proteomics*, **2014**, 96, 92-102	3.9	101
595	Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. *Journal of Translational Medicine*, **2011**, 9, 13	8.5	100
594	Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. *Journal of the American Heart Association*, **2014**, 3,	6	95
593	Benefits of preserving residual renal function in peritoneal dialysis. *Kidney International*, **2008**, S42-51	9.9	95
592	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2014**, 29, 1563-70	4.3	94
591	Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2220-8	6.9	94

590	Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. *Journal of the American Society of Nephrology: JASN*, **2000**, 11, 1266-1277	12.7	94
589	Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 110-8	6.9	93
588	Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. *Kidney International*, **2008**, 74, 585-95	9.9	93
587	ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. *Kidney International*, **1995**, 48, 1778-91	9.9	93
586	Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. *Kidney International*, **2009**, 76, 1268-76	9.9	92
585	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. *BMJ Open*, **2016**, 6, e010310	3	92
584	Pulmonary hypertension in CKD. *American Journal of Kidney Diseases*, **2013**, 61, 612-22	7.4	91
583	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. *Nephrology Dialysis Transplantation*, **2019**, 34, 208-230	4.3	88
582	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. *Nature*, **2019**, 574, 353-358	38.4	87
581	The death ligand TRAIL in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 904-14	12.7	87
580	CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1513-26	12.7	86
579	AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 175-84	6.9	86
578	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. *Oncotarget*, **2017**, 8, 18456-18485	3.3	84
577	Fibrosis: a key feature of Fabry disease with potential therapeutic implications. *Orphanet Journal of Rare Diseases*, **2013**, 8, 116	4.2	82
576	Lipid management in patients with chronic kidney disease. *Nature Reviews Nephrology*, **2018**, 14, 727-749	14.9	82
575	The MIF receptor CD74 in diabetic podocyte injury. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 353-62	12.7	81
574	TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. *Nephrology Dialysis Transplantation*, **2009**, 24, 3089-96	4.3	80
573	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *Nephrology Dialysis Transplantation*, **2017**, 32, 620-640	4.3	79

572	BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. *Nephrology Dialysis Transplantation*, **2010**, 25, 1098-108	4.3	79
571	Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 297, H2109-19	5.2	79
570	Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. *Stroke*, **2006**, 37, 2044-53	6.7	79
569	TWEAK and the progression of renal disease: clinical translation. *Nephrology Dialysis Transplantation*, **2014**, 29 Suppl 1, i54-i62	4.3	78
568	Lyso-Gb3 activates Notch1 in human podocytes. *Human Molecular Genetics*, **2015**, 24, 5720-32	5.6	77
567	Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 785-92	6.9	77
566	TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. *PLoS ONE*, **2010**, 5, e8955	3.7	77
565	End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. *Nephrology Dialysis Transplantation*, **2010**, 25, 769-75	4.3	76
564	TWEAK, a multifunctional cytokine in kidney injury. *Kidney International*, **2011**, 80, 708-18	9.9	76
563	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 301-312	18.1	75
562	The inflammatory cytokine TWEAK decreases PGC-1□expression and mitochondrial function in acute kidney injury. *Kidney International*, **2016**, 89, 399-410	9.9	74
561	Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 2061-8	9.4	74
560	Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 3329-42	5.6	74
559	The expanding spectrum of biological actions of vitamin D. *Nephrology Dialysis Transplantation*, **2010**, 25, 2850-65	4.3	73
558	3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. *Diabetes*, **2005**, 54, 2424-9	9.9	73
557	Tubular Cell Apoptosis and Cidofovir-Induced Acute Renal Failure. *Antiviral Therapy*, **2005**, 10, 185-190	1.6	73
556	Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. *FASEB Journal*, **2019**, 33, 8961-8975	0.9	72
555	Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. *American Journal of Kidney Diseases*, **1993**, 22, 822-8	7.4	72

554	European expert consensus statement on therapeutic goals in Fabry disease. *Molecular Genetics and Metabolism*, **2018**, 124, 189-203	3.7	71
553	TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 1744-55	6.9	71
552	Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 1938-1966	9.4	69
551	Statins: Could an old friend help in the fight against COVID-19?. *British Journal of Pharmacology*, **2020**, 177, 4873-4886	8.6	68
550	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. *Nephrology Dialysis Transplantation*, **2014**, 29, 232-9	4.3	67
549	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase data from the Fabry Registry. *Journal of Medical Genetics*, **2016**, 53, 495-502	5.8	67
548	p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. *Nephrology Dialysis Transplantation*, **2014**, 29, 56-64	4.3	65
547	Inflammation in Diabetic Kidney Disease. *Nephron*, **2019**, 143, 12-16	3.3	65
546	TWEAK and RIPK1 mediate a second wave of cell death during AKI. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4182-4187	11.5	64
545	Mitochondria-targeted therapies for acute kidney injury. *Expert Reviews in Molecular Medicine*, **2014** , 16, e13	6.7	64
544	Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. *Nephrology Dialysis Transplantation*, **2013**, 28, 505-17	4.3	64
543	Nephrology forum: apoptotic regulatory proteins in renal injury. *Kidney International*, **2000**, 58, 467-85	9.9	64
542	Histone lysine crotonylation during acute kidney injury in mice. *DMM Disease Models and Mechanisms*, **2016**, 9, 633-45	4.1	64
541	IL-17A is a novel player in dialysis-induced peritoneal damage. *Kidney International*, **2014**, 86, 303-15	9.9	63
540	BASP1 promotes apoptosis in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 610-21	12.7	63
539	TNF superfamily: a growing saga of kidney injury modulators. *Mediators of Inflammation*, **2010**, 2010,	4.3	63
538	Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1716-23	6.9	63
537	Klotho, phosphate and inflammation/ageing in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2012**, 27 Suppl 4, iv6-10	4.3	63

536	Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression. *Toxins*, **2018**, 10,	4.9	62
535	Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy--a Spanish multicentre experience. *Nephrology Dialysis Transplantation*, **2006**, 21 Suppl 2, ii51-5	4.3	62
534	Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. *Scientific Reports*, **2016**, 6, 27915	4.9	61
533	Haematuria: the forgotten CKD factor?. *Nephrology Dialysis Transplantation*, **2012**, 27, 28-34	4.3	61
532	The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. *Molecular Genetics and Metabolism*, **2015**, 114, 248-58	3.7	59
531	Hypertension in Chronic Kidney Disease Part 2: Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in Blood Pressure Variability and Blood Pressure Profiles. *Hypertension*, **2016**, 67, 1102-10	8.5	59
530	Targeting epigenetic DNA and histone modifications to treat kidney disease. *Nephrology Dialysis Transplantation*, **2018**, 33, 1875-1886	4.3	58
529	Targeting apoptosis in acute tubular injury. *Biochemical Pharmacology*, **2003**, 66, 1589-94	6	58
528	Contribution of apoptotic cell death to renal injury. *Journal of Cellular and Molecular Medicine*, **2001**, 5, 18-32	5.6	58
527	Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. *Kidney International*, **2012**, 82, 652-63	9.9	57
526	Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. *Nature Clinical Practice Nephrology*, **2008**, 4, 327-36		57
525	Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. *Kidney International*, **2003**, S21-6	9.9	57
524	Clinical management of the uraemic syndrome in chronic kidney disease. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 360-73	18.1	57
523	Klotho Prevents NFB Translocation and Protects Endothelial Cell From Senescence Induced by Uremia. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2015**, 70, 1198-209	6.4	56
522	TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity. *Archives of Toxicology*, **2017**, 91, 1925-1939	5.8	56
521	The burden of disease in Spain: Results from the Global Burden of Disease 2016. *Medicina Clínica*, **2018**, 151, 171-190	1	55
520	TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. *Kidney International*, **2012**, 81, 1098-107	9.9	55
519	PPAR-agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. *Laboratory Investigation*, **2010**, 90, 1517-32	5.9	55

518	Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. *Kidney International*, **1998**, 68, S25-9	9.9	54
517	Phosphate: a stealthier killer than previously thought?. *Cardiovascular Pathology*, **2012**, 21, 372-81	3.8	53
516	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. *Nephrology Dialysis Transplantation*, **2009**, 24, 278-85	4.3	53
515	Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. *Pharmaceutical Research*, **2008**, 25, 2447-61	4.5	53
514	Translational value of animal models of kidney failure. *European Journal of Pharmacology*, **2015**, 759, 205-20	5.3	52
513	Targeting inflammation in diabetic kidney disease: early clinical trials. *Expert Opinion on Investigational Drugs*, **2016**, 25, 1045-58	5.9	52
512	Focus on renal congestion in heart failure. *CKJ: Clinical Kidney Journal*, **2016**, 9, 39-47	4.5	52
511	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. *Nephrology Dialysis Transplantation*, **2018**, 33, ii4-ii14	4.3	52
510	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. *PLoS ONE*, **2017**, 12, e0173358	3.7	52
509	Albumin downregulates Klotho in tubular cells. *Nephrology Dialysis Transplantation*, **2018**, 33, 1712-1722	4.3	50
508	Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression. *Nephrology Dialysis Transplantation*, **2011**, 26, 3408-11	4.3	50
507	CXCL16 in kidney and cardiovascular injury. *Cytokine and Growth Factor Reviews*, **2014**, 25, 317-25	17.9	49
506	Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-Β independent process. *PLoS ONE*, **2010**, 5, e14145	3.7	49
505	Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. *American Journal of Pathology*, **2004**, 164, 1817-26	5.8	49
504	Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *New England Journal of Medicine*, **2018**, 378, 2540-2541	59.2	49
503	Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease. *Nutrients*, **2017**, 9,	6.7	48
502	Klotho modulates the stress response in human senescent endothelial cells. *Mechanisms of Ageing and Development*, **2012**, 133, 647-54	5.6	48
501	3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. *Kidney International*, **2005**, 68, 1303-11	9.9	48

500	HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. *Laboratory Investigation*, **2012**, 92, 32-45	5.9	47
499	Air pollution and kidney disease: review of current evidence. *CKJ: Clinical Kidney Journal*, **2019**, 12, 19-32	4.5	47
498	Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. *Molecular Genetics & Genomic Medicine*, **2018**, 6, 492	2.3	46
497	Prevalence of protein-energy wasting syndrome and its association with mortality in haemodialysis patients in a centre in Spain. *Nefrologia*, **2013**, 33, 495-505	1.5	46
496	Deferasirox nephrotoxicity-the knowns and unknowns. *Nature Reviews Nephrology*, **2014**, 10, 574-86	14.9	45
495	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. *Kidney International Supplements*, **2011**, 1, 6-9	6.3	45
494	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. *Journal of Clinical Medicine*, **2015**, 4, 1325-47	5.1	44
493	Connective tissue growth factor is a new ligand of epidermal growth factor receptor. *Journal of Molecular Cell Biology*, **2013**, 5, 323-35	6.3	44
492	Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. *Diabetes*, **2010**, 59, 1292-301	0.9	44
491	Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. *Kidney International*, **1996**, 49, 1064-70	9.9	44
490	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. *Nephrology Dialysis Transplantation*, **2017**, 32, 2079-2089	4.3	44
489	Spanish guidelines for the management of autosomal dominant polycystic kidney disease. *Nephrology Dialysis Transplantation*, **2014**, 29 Suppl 4, iv95-105	4.3	43
488	Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". *Toxins*, **2017**, 9,	4.9	43
487	Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. *Translational Research*, **2015**, 166, 474-484.e4	11	43
486	Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice. *PLoS ONE*, **2013**, 8, e83713	3.7	43
485	TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. *Frontiers in Bioscience - Landmark*, **2007**, 12, 3648-55	2.8	43
484	Epithelial differentiation of metanephric mesenchymal cells after stimulation with hepatocyte growth factor or embryonic spinal cord. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 5286-90	11.5	43
483	The role of endothelial glycocalyx in health and disease. *CKJ: Clinical Kidney Journal*, **2019**, 12, 611-619	4.5	42

482	The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases. *Biomolecules*, **2020**, 10,	5.9	42
481	DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells. *Epigenetics*, **2013**, 8, 66-78	5.7	42
480	TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. *Journal of Pathology*, **2013**, 231, 480-94	9.4	42
479	New paradigms in cell death in human diabetic nephropathy. *Kidney International*, **2010**, 78, 737-44	9.9	42
478	Considering TWEAK as a target for therapy in renal and vascular injury. *Cytokine and Growth Factor Reviews*, **2009**, 20, 251-8	17.9	42
477	PGC-1α deficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI. *Journal of Pathology*, **2019**, 249, 65-78	9.4	41
476	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. *Nephrology Dialysis Transplantation*, **2014**, 29, 1275-84	4.3	41
475	Fn14 in podocytes and proteinuric kidney disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 2232-43	6.9	41
474	Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. *Kidney International*, **2009**, 75, 227-34	9.9	41
473	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. *Nature Reviews Nephrology*, **2011**, 8, 141-50	14.9	40
472	Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. *PLoS ONE*, **2013**, 8, e72387	3.7	40
471	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. *Cardiovascular Research*, **2009**, 83, 586-94	9.9	40
470	Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. *PLoS ONE*, **2008**, 3, e3959	3.7	40
469	Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. *American Journal of Physiology - Renal Physiology*, **2016**, 311, F1329-F1340	4.3	40
468	Hypertension in Chronic Kidney Disease Part 1: Out-of-Office Blood Pressure Monitoring: Methods, Thresholds, and Patterns. *Hypertension*, **2016**, 67, 1093-101	8.5	40
467	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. *Scientific Reports*, **2017**, 7, 16915	4.9	39
466	Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 504-519	12.7	39
465	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. *Kidney International Supplements*, **2011**, 1, 10-12	6.3	38

464	Vitamin D receptor activation and cardiovascular disease. *Nephrology Dialysis Transplantation*, **2012**, 27 Suppl 4, iv17-21	4.3	38
463	The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1566-74	12.7	37
462	CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. *CKJ: Clinical Kidney Journal*, **2014**, 7, 519-23	4.5	37
461	MXRA5 is a TGF-β1-regulated human protein with anti-inflammatory and anti-fibrotic properties. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 154-164	5.6	37
460	Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation. *Clinical Science*, **2014**, 127, 19-31	6.5	37
459	TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. *Frontiers in Immunology*, **2013**, 4, 447	8.4	37
458	Antioxidants in kidney diseases: the impact of bardoxolone methyl. *International Journal of Nephrology*, **2012**, 2012, 321714	1.7	37
457	Phosphorus and nutrition in chronic kidney disease. *International Journal of Nephrology*, **2012**, 2012, 597605	1.7	37
456	Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. *PLoS ONE*, **2015**, 10, e0136863	3.7	37
455	Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2442-2449	12.7	37
454	The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. *Kidney International*, **2021**, 99, 986-998	9.9	37
453	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. *Diabetes Care*, **2018**, 41, 1817-1820	14.6	36
452	The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. *Laboratory Investigation*, **2013**, 93, 812-24	5.9	36
451	Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. *Nephrology Dialysis Transplantation*, **2010**, 25, 4103-6	4.3	36
450	Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation. *American Journal of Medicine*, **2016**, 129, 1259-1263	2.4	36
449	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *Journal of Hypertension*, **2017**, 35, 657-676	1.9	35
448	HIV and kidney diseases: 35 years of history and consequences. *CKJ: Clinical Kidney Journal*, **2016**, 9, 772-781	4.5	35
447	Severe everolimus-associated pneumonitis in a renal transplant recipient. *Nephrology Dialysis Transplantation*, **2008**, 23, 3353-5	4.3	35

446	Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation. *Journal of Pathology*, **2018**, 244, 227-241	9.4	35
445	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. *CKJ: Clinical Kidney Journal*, **2015**, 8, 503-10	4.5	34
444	Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. *Molecular Genetics and Metabolism*, **2015**, 114, 242-7	3.7	34
443	Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy. *Nephron Clinical Practice*, **2012**, 121, c42-53		34
442	Role of endogenous vascular endothelial growth factor in tubular cell protection against acute cyclosporine toxicity. *Transplantation*, **2002**, 74, 1618-24	1.8	34
441	Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 89-105	6.4	33
440	TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF-B pathway and ERK activation. *Journal of Cellular Physiology*, **2015**, 230, 1580-93	7	33
439	Gremlin activates the Smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. *BioMed Research International*, **2014**, 2014, 802841	3	33
438	Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. *Nephron Experimental Nephrology*, **2012**, 122, 62-74		33
437	Angiotensin II contributes to renal fibrosis independently of Notch pathway activation. *PLoS ONE*, **2012**, 7, e40490	3.7	33
436	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. *Molecular Genetics and Metabolism*, **2019**, 126, 224-235	3.7	33
435	MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. *Cytokine and Growth Factor Reviews*, **2013**, 24, 23-40	17.9	32
434	Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. *Kidney International*, **2005**, 67, 592-601	9.9	32
433	Peritoneal Dialysis Retardation of Progression of Advanced Renal Failure. *Peritoneal Dialysis International*, **2002**, 22, 239-242	2.8	32
432	Podocytes are new cellular targets of haemoglobin-mediated renal damage. *Journal of Pathology*, **2018**, 244, 296-310	9.4	32
431	TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFB. *Cell Death and Disease*, **2016**, 7, e2305	9.8	31
430	A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. *PLoS ONE*, **2013**, 8, e51992	3.7	31
429	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. *Kidney International*, **2010**, 78, 1275-80	9.9	31

428	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. *Kidney International Supplements*, **2011**, 1, 21-23	6.3	31
427	Phenytoin inhibits necroptosis. *Cell Death and Disease*, **2018**, 9, 359	9.8	30
426	Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. *International Urology and Nephrology*, **2012**, 44, 1731-44	2.3	30
425	GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. *Toxicological Sciences*, **2012**, 127, 425-37	4.4	30
424	Bisphenol A is an exogenous toxin that promotes mitochondrial injury and death in tubular cells. *Environmental Toxicology*, **2018**, 33, 325-332	4.2	30
423	Capillary rarefaction from the kidney point of view. *CKJ: Clinical Kidney Journal*, **2018**, 11, 295-301	4.5	30
422	Osteoprotegerin and kidney disease. *Journal of Nephrology*, **2014**, 27, 607-17	4.8	29
421	Calcineurin inhibitors recruit protein kinases JAK2 and JNK, TLR signaling and the UPR to activate NF-B-mediated inflammatory responses in kidney tubular cells. *Toxicology and Applied Pharmacology*, **2013**, 272, 825-41	4.6	29
420	Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease. *Nephron*, **2017**, 136, 263-267	3.3	29
419	Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARn the associated hypertrophy. *Journal of Proteomics*, **2012**, 75, 1816-29	3.9	29
418	Bisphenol a in chronic kidney disease. *International Journal of Nephrology*, **2013**, 2013, 437857	1.7	29
417	Coronavirus disease 2019 in chronic kidney disease. *CKJ: Clinical Kidney Journal*, **2020**, 13, 297-306	4.5	29
416	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T´cell immunity in naive and COVID-19 recovered individuals. *Cell Reports*, **2021**, 36, 109570	10.6	29
415	Albumin-induced apoptosis of tubular cells is modulated by BASP1. *Cell Death and Disease*, **2015**, 6, e1644	9.8	28
414	Bcl3: a regulator of NF-B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. *Experimental and Molecular Medicine*, **2017**, 49, e352	12.8	28
413	Pathogenesis of glomerular haematuria. *World Journal of Nephrology*, **2015**, 4, 185-95	3.6	28
412	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. *BMC Systems Biology* , **2013**, 7, 110	3.5	28
411	Undiagnosed hepatitis C virus infection in hemodialysis patients: value of HCV RNA and liver enzyme levels. *Kidney International*, **1996**, 50, 2027-31	9.9	28

410	Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function. *Therapeutic Advances in Drug Safety*, **2015**, 6, 166-76	3.5	27
409	Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect. *Journal of Leukocyte Biology*, **2015**, 98, 257-69	6.5	27
408	Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). *Cardiovascular Drugs and Therapy*, **2018**, 32, 255-263	3.9	27
407	A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. *PLoS ONE* , **2009**, 4, e6634	3.7	27
406	Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. *Kidney International*, **2003**, 64, 181-91	9.9	27
405	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. *Journal of Clinical Medicine*, **2020**, 9,	5.1	27
404	Tubular cell apoptosis and cidofovir-induced acute renal failure. *Antiviral Therapy*, **2005**, 10, 185-90	1.6	27
403	Alkalinization potentiates vascular calcium deposition in an uremic milieu. *Journal of Nephrology*, **2009**, 22, 647-53	4.8	27
402	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2368-2383	6.7	26
401	Progress in the development of animal models of acute kidney injury and its impact on drug discovery. *Expert Opinion on Drug Discovery*, **2013**, 8, 879-95	6.2	26
400	Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension. *Frontiers in Pharmacology*, **2019**, 10, 1015	5.6	25
399	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. *Journal of Clinical Medicine*, **2019**, 8,	5.1	25
398	Phosphodiesterase type 5 inhibitors and kidney disease. *International Urology and Nephrology*, **2015** , 47, 1521-8	2.3	25
397	Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. *Kidney International*, **2003**, S52-6	9.9	25
396	Long-term blood pressure control prevents oxidative renal injury. *Antioxidants and Redox Signaling*, **2005**, 7, 1285-93	8.4	25
395	Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. *Nefrologia*, **2013**, 33, 716-26	1.5	25
394	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. *Nefrologia*, **2019**, 39, 29-34	1.5	25
393	Potential Dangers of Serum Urate-Lowering Therapy. *American Journal of Medicine*, **2019**, 132, 457-467	2.4	25

392	Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. *Scientific Reports*, **2018**, 8, 15940	4.9	25
391	Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and HS availability. *Journal of Molecular Medicine*, **2017**, 95, 1399-1409	5.5	24
390	Designing drugs that combat kidney damage. *Expert Opinion on Drug Discovery*, **2015**, 10, 541-56	6.2	24
389	Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. *Molecular Genetics and Metabolism*, **2012**, 105, 525-7	3.7	24
388	Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. *Nephrology Dialysis Transplantation*, **2001**, 16, 2188-93	4.3	24
387	The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-B pathway and proinflammatory factors in vascular smooth muscle cells. *Antioxidants and Redox Signaling*, **2015**, 22, 29-47	8.4	23
386	Targeting of regulated necrosis in kidney disease. *Nefrologia*, **2018**, 38, 125-135	1.5	23
385	Non-canonical NFB activation promotes chemokine expression in podocytes. *Scientific Reports*, **2016**, 6, 28857	4.9	23
384	Regulation of apoptosis by lethal cytokines in human mesothelial cells. *Kidney International*, **2003**, 64, 321-30	9.9	23
383	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. *CKJ: Clinical Kidney Journal*, **2019**, 12, 313-321	4.5	22
382	Clarifying the concept of chronic kidney disease for non-nephrologists. *CKJ: Clinical Kidney Journal*, **2019**, 12, 258-261	4.5	22
381	IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2015**, 1853, 3224-34	4.9	22
380	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. *Drugs*, **2018**, 78, 215-229	12.1	22
379	Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. *Nephrology Dialysis Transplantation*, **2018**, 33, 2156-2164	4.3	22
378	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. *Molecular Genetics and Metabolism*, **2016**, 119, 151-9	3.7	22
377	Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury. *Seminars in Nephrology*, **2016**, 36, 189-98	4.8	22
376	Mitogen-Activated Protein Kinase 14 Promotes AKI. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 823-836	12.7	22
375	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. *Hypertension*, **2015**, 66, 3-9	8.5	21

374	Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. *Frontiers in Pharmacology*, **2019**, 10, 740	5.6	21
373	Lesinurad: what the nephrologist should know. *CKJ: Clinical Kidney Journal*, **2017**, 10, 679-687	4.5	21
372	Role of platelet-activating factor in adriamycin-induced nephropathy in rats. *European Journal of Pharmacology*, **1987**, 138, 119-23	5.3	21
371	Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis. *Frontiers in Pharmacology*, **2018**, 9, 1195	5.6	21
370	Next-generation phosphate binders: focus on iron-based binders. *Drugs*, **2014**, 74, 863-77	12.1	20
369	Role of chemokines in proteinuric kidney disorders. *Expert Reviews in Molecular Medicine*, **2014**, 16, e3	6.7	20
368	Notch3 and kidney injury: never two without three. *Journal of Pathology*, **2012**, 228, 266-73	9.4	20
367	Subclinical versus overt obesity in dialysis patients: more than meets the eye. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv175-81	4.3	20
366	Tyrphostins as potential therapeutic agents for acute kidney injury. *Current Medicinal Chemistry*, **2010**, 17, 974-86	4.3	20
365	Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. *Toxicological Sciences*, **2009**, 111, 413-23	4.4	20
364	Modulation of renal tubular cell survival: where is the evidence?. *Current Medicinal Chemistry*, **2006**, 13, 449-54	4.3	20
363	Defining protein-energy wasting syndrome in chronic kidney disease: prevalence and clinical implications. *Nefrologia*, **2014**, 34, 507-19	1.5	20
362	Increased urinary CD80 excretion and podocyturia in Fabry disease. *Journal of Translational Medicine*, **2016**, 14, 289	8.5	20
361	Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials. *CKJ: Clinical Kidney Journal*, **2019**, 12, 110-112	4.5	19
360	Angiotensin II, via angiotensin receptor type 1/nuclear factor-B activation, causes a synergistic effect on interleukin-1-induced inflammatory responses in cultured mesangial cells. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2015**, 16, 23-32	3	19
359	NFBiz protein downregulation in acute kidney injury: Modulation of inflammation and survival in tubular cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 635-646	6.9	19
358	Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. *Cytokine and Growth Factor Reviews*, **2016**, 28, 71-7	17.9	19
357	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). *Toxins*, **2018**, 10,	4.9	19

356	Targeting chemokines in proteinuria-induced renal disease. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 833-45	6.4	19
355	Inhibition of Caspases Improves Bacterial Clearance in Experimental Peritonitis. *Peritoneal Dialysis International*, **2003**, 23, 123-126	2.8	19
354	Modulation of survival in osteoblasts from postmenopausal women. *Bone*, **2004**, 35, 170-7	4.7	19
353	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. *International Journal of Public Health*, **2018**, 63, 177-186	4	19
352	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. *Diabetic Medicine*, **2018**, 35, 1375-1382	3.5	19
351	Tweak up-regulates endothelin-1 system in mouse and human endothelial cells. *Cardiovascular Research*, **2017**, 113, 207-221	9.9	18
350	Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. *Calcified Tissue International*, **2016**, 99, 121-30	3.9	18
349	Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology. *CKJ: Clinical Kidney Journal*, **2015**, 8, 14-22	4.5	18
348	The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. *Kidney International Supplements*, **2011**, 1, 2-5	6.3	18
347	The effect of chronic kidney disease on lipid metabolism. *International Urology and Nephrology*, **2019**, 51, 265-277	2.3	18
346	Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. *Scientific Reports*, **2017**, 7, 41510	4.9	17
345	Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2017**, 125, 8-13	2.8	17
344	Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study. *Peritoneal Dialysis International*, **2015**, 35, 530-6	2.8	17
343	Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	17
342	Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	17
341	Gremlin activates the Notch pathway linked to renal inflammation. *Clinical Science*, **2018**, 132, 1097-1115	6.5	17
340	Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. *International Urology and Nephrology*, **2016**, 48, 1129-36	2.3	17
339	Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. *BioMed Research International* , **2015**, 2015, 783538	3	17

338	Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. *Kidney International*, **2008**, S88-93	9.9	17
337	A slit in podocyte death. *Current Medicinal Chemistry*, **2008**, 15, 1645-54	4.3	17
336	3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes. *Current Medicinal Chemistry*, **2006**, 13, 2695-702	4.3	17
335	TWEAK promotes peritoneal inflammation. *PLoS ONE*, **2014**, 9, e90399	3.7	17
334	PCSK9 in diabetic kidney disease. *European Journal of Clinical Investigation*, **2016**, 46, 779-86	4.6	16
333	Circulating CXCL16 in Diabetic Kidney Disease. *Kidney and Blood Pressure Research*, **2016**, 41, 663-671	3.1	16
332	CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury. *Journal of Pathology*, **2018**, 246, 191-204	9.4	16
331	Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. *Current Opinion in Nephrology and Hypertension*, **2014**, 23, 93-100	3.5	16
330	Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. *Proteomics - Clinical Applications*, **2011**, 5, 233-40	3.1	16
329	Obstructive renal injury: from fluid mechanics to molecular cell biology. *Research and Reports in Urology*, **2010**, 2, 41-55	1.3	16
328	An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. *CKJ: Clinical Kidney Journal*, **2020**, 13, 981-993	4.5	16
327	The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study. *Kidney and Blood Pressure Research*, **2016**, 41, 1016-1024	3.1	16
326	Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1. *CKJ: Clinical Kidney Journal*, **2019**, 12, 420-426	4.5	16
325	Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. *CKJ: Clinical Kidney Journal*, **2019**, 12, 629-638	4.5	15
324	Effective Nephroprotection Against Acute Kidney Injury with a Star-Shaped Polyglutamate-Curcuminoid Conjugate. *Scientific Reports*, **2020**, 10, 2056	4.9	15
323	Urine 2DE proteome analysis in healthy condition and kidney disease. *Electrophoresis*, **2014**, 35, 2634-41	3.6	15
322	3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. *Archives of Toxicology*, **2014**, 88, 597-608	5.8	15
321	Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function. *American Journal of Transplantation*, **2017**, 17, 733-743	8.7	15

320	TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. *Mediators of Inflammation*, **2015**, 2015, 506041	4.3	15
319	Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort. *Human Immunology*, **2015**, 76, 75-8	2.3	15
318	High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients. *Clinical and Experimental Nephrology*, **2012**, 16, 945-51	2.5	15
317	Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. *PLoS ONE*, **2012**, 7, e47440	3.7	15
316	Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2. *Kidney International*, **2013**, 83, 825-34	9.9	15
315	Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?. *Nephrology Dialysis Transplantation*, **2012**, 27, 478-81	4.3	15
314	A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients. *Clinical Transplantation*, **2008**, 22, 722-9	3.8	15
313	3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization. *Nephrology Dialysis Transplantation*, **2008**, 23, 3307-15	4.3	15
312	Colchicine in Renal Medicine: New Virtues of an Ancient Friend. *Blood Purification*, **2017**, 43, 125-135	3.1	14
311	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. *Journal of Clinical Medicine*, **2020**, 9,	5.1	14
310	The demise of calcium-based phosphate binders. *Lancet, The*, **2013**, 382, 1232-4	40	14
309	CD74 in Kidney Disease. *Frontiers in Immunology*, **2015**, 6, 483	8.4	14
308	Humble kidneys predict mighty heart troubles. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 489-91	18.1	14
307	A role for the membrane proteome in human chronic kidney disease erythrocytes. *Translational Research*, **2012**, 160, 374-83	11	14
306	Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. *Proteomics - Clinical Applications*, **2011**, 5, 281-8	3.1	14
305	Unravelling fibrosis: two newcomers and an old foe. *Nephrology Dialysis Transplantation*, **2010**, 25, 3492-5	4.3	14
304	Inflammation both increases and causes resistance to FGF23 in normal and uremic rats. *Clinical Science*, **2020**, 134, 15-32	6.5	14
303	Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis?. *Scientific Reports*, **2016**, 6, 19667	4.9	14

302	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. *Acta Diabetologica*, **2021**, 58, 81-91	3.9	14
301	Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men. *CKJ: Clinical Kidney Journal*, **2018**, 11, 1-6	4.5	14
300	Inhibition of caspases improves bacterial clearance in experimental peritonitis. *Peritoneal Dialysis International*, **2003**, 23, 123-6	2.8	14
299	Diagnosis and treatment of Fabry disease. *Medicina Clínica*, **2017**, 148, 132-138	1	13
298	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5406-5420	5.6	13
297	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. *Nephrology Dialysis Transplantation*, **2019**, 34, 923-933	4.3	13
296	NIK as a Druggable Mediator of Tissue Injury. *Trends in Molecular Medicine*, **2019**, 25, 341-360	11.5	13
295	Timing of eculizumab therapy for C3 glomerulonephritis. *CKJ: Clinical Kidney Journal*, **2015**, 8, 449-52	4.5	13
294	Ferroptosis and kidney disease. *Nefrologia*, **2020**, 40, 384-394	1.5	13
293	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. *Europace*, **2020**, 22, 496-505	3.9	13
292	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, i13-i23	4.3	13
291	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. *Angiology*, **2020**, 71, 315-323	2.1	13
290	Translational science in chronic kidney disease. *Clinical Science*, **2017**, 131, 1617-1629	6.5	13
289	Individualization of dialysate calcium concentration according to baseline pre-dialysis serum calcium. *Blood Purification*, **2014**, 38, 224-33	3.1	13
288	Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. *American Journal of Physiology - Renal Physiology*, **2014**, 307, F75-85	4.3	13
287	The Contribution of Histone Crotonylation to Tissue Health and Disease: Focus on Kidney Health. *Frontiers in Pharmacology*, **2020**, 11, 393	5.6	13
286	Criteria for classification of protein-energy wasting in dialysis patients: impact on prevalence. *British Journal of Nutrition*, **2019**, 121, 1271-1278	3.6	12
285	Use of sevelamer in chronic kidney disease: beyond phosphorus control. *Nefrologia*, **2015**, 35, 207-17	1.5	12

284	Molecular pathways driving omeprazole nephrotoxicity. *Redox Biology*, **2020**, 32, 101464	11.3	12
283	Albuminuria Downregulation of the Anti-Aging Factor Klotho: The Missing Link Potentially Explaining the Association of Pathological Albuminuria with Premature Death. *Advances in Therapy*, **2020**, 37, 62-72	4.1	12
282	Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. *CKJ: Clinical Kidney Journal*, **2017**, 10, 188-191	4.5	12
281	Macrophages and recently identified forms of cell death. *International Reviews of Immunology*, **2014** , 33, 9-22	4.6	12
280	Paricalcitol for reduction of albuminuria in diabetes. *Lancet, The*, **2011**, 377, 635-6, author reply 636-7	40	12
279	Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. *Biochemical and Biophysical Research Communications*, **2010**, 397, 576-9	3.4	12
278	AG490 promotes HIF-1□accumulation by inhibiting its hydroxylation. *Current Medicinal Chemistry*, **2012**, 19, 4014-23	4.3	12
277	Trail and kidney disease. *Frontiers in Bioscience - Landmark*, **2009**, 14, 3740-9	2.8	12
276	Will Modulation of Cell Death Increase PD Technique Survival?. *Peritoneal Dialysis International*, **2004**, 24, 105-114	2.8	12
275	Role and regulation of apoptotic cell death in the kidney. Y2K update. *Frontiers in Bioscience - Landmark*, **2000**, 5, D735-49	2.8	12
274	Molecular mediators of favism-induced acute kidney injury. *Clinical Nephrology*, **2014**, 81, 203-9	2.1	12
273	Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. *Expert Review of Proteomics*, **2019**, 16, 77-92	4.2	12
272	Loss of NLRP6 expression increases the severity of acute kidney injury. *Nephrology Dialysis Transplantation*, **2020**, 35, 587-598	4.3	12
271	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. *BMC Medicine*, **2018**, 16, 158	11.4	12
270	Salt Intake and Immunity. *Hypertension*, **2018**, 72, 19-23	8.5	12
269	Hyponatraemia diagnosis and treatment clinical practice guidelines. *Nefrologia*, **2017**, 37, 370-380	1.5	11
268	Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. *JIMD Reports*, **2018**, 38, 45-51	1.9	11
267	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. *Nephrology Dialysis Transplantation*, **2017**, 32, 1967-1976	4.3	11

266	The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. *Nefrologia*, **2019**, 39, 29-34	0.4	11
265	Targeting of regulated necrosis in kidney disease. *Nefrologia*, **2018**, 38, 125-135	0.4	11
264	Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development. *CKJ: Clinical Kidney Journal*, **2018**, 11, 491-495	4.5	11
263	TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells. *PLoS ONE*, **2018**, 13, e0199391	3.7	11
262	Dietary Care for ADPKD Patients: Current Status and Future Directions. *Nutrients*, **2019**, 11,	6.7	11
261	Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 293-303	6.9	11
260	2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. *CKJ: Clinical Kidney Journal*, **2015**, 8, 243-7	4.5	11
259	The use of echocardiography in observational clinical trials: the EURECA-m registry. *Nephrology Dialysis Transplantation*, **2013**, 28, 19-23	4.3	11
258	Laser therapy in metabolic syndrome-related kidney injury. *Photochemistry and Photobiology*, **2013**, 89, 953-60	3.6	11
257	Emphysematous pyelonephritis in dialysis patient after embolization of failed allograft. *Urology*, **2007**, 70, 372.e17-9	1.6	11
256	Tight blood pressure control decreases apoptosis during renal damage. *Kidney International*, **2004**, 65, 811-22	9.9	11
255	Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?. *Journal of Nephropathology*, **2012**, 1, 152-4	0.6	11
254	Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations. *Biomedicine and Pharmacotherapy*, **2020**, 121, 109684	7.5	11
253	Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34. *Nephrology Dialysis Transplantation*, **2016**, 31, 1409-16	4.3	11
252	MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. *Nephrology Dialysis Transplantation*, **2019**, 34, 1498-1507	4.3	11
251	MAP3K kinases and kidney injury. *Nefrologia*, **2019**, 39, 568-580	1.5	10
250	Diagnostic Utility of Exome Sequencing for Kidney Disease. *New England Journal of Medicine*, **2019**, 380, 2078	59.2	10
249	Biocompatibility reduces inflammation-induced apoptosis in mesothelial cells exposed to peritoneal dialysis fluid. *Blood Purification*, **2015**, 39, 200-209	3.1	10

248	Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. *Journal of Bone and Mineral Metabolism*, **2016**, 34, 587-98	2.9	10
247	Use of sevelamer in chronic kidney disease: beyond phosphorus control. *Nefrologia*, **2015**, 35, 207-217	0.4	10
246	Familial C4B deficiency and immune complex glomerulonephritis. *Clinical Immunology*, **2010**, 137, 166-75	9	10
245	Renal cell loss through cell suicide. *Kidney International*, **2000**, 58, 2235-6	9.9	10
244	Glomerular up-regulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. *Kidney International*, **1996**, 50, 908-19	9.9	10
243	Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits. *Nephron*, **1992**, 60, 248	3.3	10
242	Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing. *Nefrologia*, **2012**, 32, 715-23	1.5	10
241	Protective Role of Nrf2 in Renal Disease. *Antioxidants*, **2020**, 10,	7.1	10
240	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. *Hypertension*, **2021**, 77, 1029-1035	8.5	10
239	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. *Nephrology Dialysis Transplantation*, **2021**,	4.3	10
238	Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis. *CKJ: Clinical Kidney Journal*, **2016**, 9, 381-6	4.5	10
237	Multilayered Interplay Between Fructose and Salt in Development of Hypertension. *Hypertension*, **2019**, 73, 265-272	8.5	10
236	Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal. *Pharmacological Research*, **2018**, 129, 535-543	10.2	10
235	Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. *International Journal of Public Health*, **2018**, 63, 63-77	4	10
234	The Future of IL-1 Targeting in Kidney Disease. *Drugs*, **2018**, 78, 1073-1083	12.1	10
233	Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. *Cell Death and Disease*, **2018**, 9, 118	9.8	9
232	Atherosclerotic renal artery stenosis in the post-CORAL era part 1: the renal penumbra concept and next-generation functional diagnostic imaging. *Journal of the American Society of Hypertension*, **2016**, 10, 360-7		9
231	Lyso-Gb3 modulates the gut microbiota and decreases butyrate production. *Scientific Reports*, **2019** , 9, 12010	4.9	9

230	Peritonitis due to Microbacterium sp in a patient on cycler peritoneal dialysis. *Peritoneal Dialysis International*, **2010**, 30, 669-70	2.8	9
229	Major pathways of the reno-cardiovascular link: the sympathetic and renin-angiotensin systems. *Kidney International Supplements*, **2011**, 1, 13-16	6.3	9
228	Dual-specificity phosphatases are implicated in severe hyperplasia and lack of response to FGF23 of uremic parathyroid glands from rats. *Endocrinology*, **2012**, 153, 1627-37	4.8	9
227	A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. *PLoS ONE*, **2017**, 12, e0173831	3.7	9
226	Translational study of the Notch pathway in hypertensive nephropathy. *Nefrologia*, **2014**, 34, 369-76	1.5	9
225	TWEAKing renal injury. *Frontiers in Bioscience - Landmark*, **2008**, 13, 580-9	2.8	9
224	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. *Nephrology Dialysis Transplantation*, **2020**,	4.3	9
223	The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients. *Journal of Clinical Medicine*, **2020**, 9,	5.1	9
222	Role of Klotho in the Development of Essential Hypertension. *Hypertension*, **2021**, 77, 740-750	8.5	9
221	Apoptosis inducing factor (AIF) mediates lethal redox stress induced by menadione. *Oncotarget*, **2016**, 7, 76496-76507	3.3	9
220	Reactions to Synthetic Membranes Dialyzers: Is there an Increase in Incidence?. *Kidney and Blood Pressure Research*, **2019**, 44, 907-914	3.1	8
219	Atherosclerotic renal artery stenosis in the post-CORAL era part 2: new directions in Transcatheter Nephron Salvage following flawed revascularization trials. *Journal of the American Society of Hypertension*, **2016**, 10, 368-77		8
218	Influence of dialysis membrane composition on plasma bisphenol A levels during online hemodiafiltration. *PLoS ONE*, **2018**, 13, e0193288	3.7	8
217	MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy. *CKJ: Clinical Kidney Journal*, **2019**, 12, 488-493	4.5	8
216	Molecular evidence of field cancerization initiated by diabetes in colon cancer patients. *Molecular Oncology*, **2019**, 13, 857-872	7.9	8
215	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. *CKJ: Clinical Kidney Journal*, **2019**, 12, 861-870	4.5	8
214	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort. *Gene*, **2013**, 527, 670-2	3.8	8
213	Gliotoxin inhibits neointimal hyperplasia after vascular injury in rats. *Journal of Vascular Research*, **2009**, 46, 278-89	1.9	8

212	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. *Kidney International Supplements*, **2011**, 1, 17-20	6.3	8
211	Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage. *JIMD Reports*, **2013**, 8, 51-6	1.9	8
210	Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. *Nephrology Dialysis Transplantation*, **2012**, 27, 2720-33	4.3	8
209	Lethal activity of FADD death domain in renal tubular epithelial cells. *Kidney International*, **2006**, 69, 2205-11	5.9	8
208	Cortisol levels are associated with mortality risk in hemodialysis patients. *Clinical Nephrology*, **2014**, 82, 247-56	2.1	8
207	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. *Nephrology Dialysis Transplantation*, **2021**,	4.3	8
206	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals		8
205	Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients. *Kidney and Blood Pressure Research*, **2021**, 46, 126-134	3.1	8
204	Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. *International Journal of Public Health*, **2018**, 63, 79-96	4	8
203	Incidence of Hypersensitivity Reactions During Hemodialysis. *Kidney and Blood Pressure Research*, **2018**, 43, 1472-1478	3.1	8
202	[Impact of the COVID-19 pandemic on Spanish Nephrology Services]. *Nefrologia*, **2020**, 40, 579-584	1.5	7
201	Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2018**, 13, 577-584	6.9	7
200	The chaos of hypertension guidelines for chronic kidney disease patients. *CKJ: Clinical Kidney Journal*, **2019**, 12, 771-777	4.5	7
199	Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema. *Journal of Bone and Mineral Metabolism*, **2013**, 31, 703-7	2.9	7
198	Bcl-xL Prevents Peritoneal Dialysis Solution-Induced Leukocyte Apoptosis. *Peritoneal Dialysis International*, **2008**, 28, 48-52	2.8	7
197	Peritoneal defence--lessons learned which apply to diabetes complications. *Nephrology Dialysis Transplantation*, **2006**, 21 Suppl 2, ii12-5	4.3	7
196	Antiplatelet therapy alters iron requirements in hemodialysis patients. *American Journal of Kidney Diseases*, **2000**, 36, 80-7	7.4	7
195	Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. *Journal of Nephrology*, **2021**, 34, 649-659	4.8	7

194	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. *Journal of Diabetes and Its Complications*, **2020**, 34, 107707	3.2	7
193	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. *Toxicology and Applied Pharmacology*, **2021**, 414, 115412	4.6	7
192	Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. *Journal of Nephrology*, **2021**, 34, 1819-1832	4.8	7
191	Atrial fibrillation in chronic kidney disease. *European Journal of Internal Medicine*, **2016**, 33, 3-13	3.9	7
190	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. *Nephrology Dialysis Transplantation*, **2021**,	4.3	7
189	Role of Macrophages and Related Cytokines in Kidney Disease. *Frontiers in Medicine*, **2021**, 8, 688060	4.9	7
188	The ERA Registry Annual Report 2019: summary and age comparisons.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 452-472	4.5	7
187	Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification. *PLoS ONE*, **2017**, 12, e0183730	3.7	6
186	Paricalcitol and albuminuria: tread carefully. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 3-5	18.1	6
185	Enzyme replacement therapy dose and Fabry nephropathy. *Nephrology Dialysis Transplantation*, **2018**, 33, 1284-1289	4.3	6
184	Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?. *CKJ: Clinical Kidney Journal*, **2014**, 7, 437-41	4.5	6
183	Application of the new cholesterol guidelines. *New England Journal of Medicine*, **2014**, 371, 79	59.2	6
182	The meaning of urinary creatinine concentration. *Kidney International*, **2011**, 79, 791	9.9	6
181	Endovascular repair of mycotic aneurysms of the aorta: an alternative to conventional bypass surgery in patients with acute sepsis. *Scandinavian Journal of Infectious Diseases*, **2007**, 39, 268-71		6
180	Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
179	Givosiran for Acute Intermittent Porphyria. *New England Journal of Medicine*, **2020**, 383, 1989	59.2	6
178	Renin-angiotensin system and inflammation update. *Molecular and Cellular Endocrinology*, **2021**, 529, 111254	4.4	6
177	Podocyturia: why it may have added value in rare diseases. *CKJ: Clinical Kidney Journal*, **2019**, 12, 49-52	4.5	6

176	Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. *Journal of Hypertension*, **2021**, 39, 1090-1097	1.9	6
175	Effect of Coffee Consumption on Renal Outcome: A Systematic Review and Meta-Analysis of Clinical Studies. *Journal of Renal Nutrition*, **2021**, 31, 5-20	3	6
174	Mass Disasters and Burnout in Nephrology Personnel: From Earthquakes and Hurricanes to COVID-19 Pandemic. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 829-837	6.9	6
173	Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction. *Molecular Oncology*, **2019**, 13, 1887-1897	7.9	5
172	Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD. *Kidney International*, **2015**, 88, 194	9.9	5
171	Ferroptosis and kidney disease. *Nefrologia*, **2020**, 40, 384-394	0.4	5
170	TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 2026-2042	12.7	5
169	Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. *ESC Heart Failure*, **2020**, 7, 825-834	3.7	5
168	Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. *International Journal of Nephrology*, **2017**, 2017, 1287289	1.7	5
167	Risk in dosing regimens for 25-OH vitamin D supplementation in chronic haemodialysis patients. *Nephron*, **2012**, 121, c112-9	3.3	5
166	Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes. *CKJ: Clinical Kidney Journal*, **2015**, 8, 576-9	4.5	5
165	The fate of triaged and rejected manuscripts. *Nephrology Dialysis Transplantation*, **2015**, 30, 1947-50	4.3	5
164	Bicarbonate therapy, phosphate binders, and risk for vascular calcification. *Kidney International*, **2014**, 86, 1056	9.9	5
163	Reality and desire in the care of advanced chronic kidney disease. *CKJ: Clinical Kidney Journal*, **2010**, 3, 431-5	4.5	5
162	Undetectable serum calcidiol: not everything that glitters is gold. *CKJ: Clinical Kidney Journal*, **2012**, 5, 37-40	4.5	5
161	The human plasma lipidome. *New England Journal of Medicine*, **2012**, 366, 668; author reply 668-9	59.2	5
160	Concentrated ascitic fluid reinfusion in cirrhotic patients: a simplified method. *American Journal of Kidney Diseases*, **1997**, 29, 392-8	7.4	5
159	Pseudomonas oryzihabitans peritonitis in a patient on continuous ambulatory peritoneal dialysis. *Clinical Microbiology and Infection*, **2002**, 8, 607-8	9.5	5

158	Circulating endothelial cells in sickle cell anemia. *New England Journal of Medicine*, **1998**, 338, 1162; author reply 1162-3	59.2	5
157	Salmonella enteritidis empyema complicating lupus pleuritis. *Postgraduate Medical Journal*, **1991**, 67, 778-9	2	5
156	Colon cancer modulation by a diabetic environment: A single institutional experience. *PLoS ONE*, **2017**, 12, e0172300	3.7	5
155	Calcific uremic arteriolopathy while on cinacalcet. *Journal of Postgraduate Medicine*, **2011**, 57, 51-2	0.8	5
154	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. *CKJ: Clinical Kidney Journal*, **2020**, 13, 913-925	4.5	5
153	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. *Nephrology Dialysis Transplantation*, **2021**,	4.3	5
152	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. *Mitochondrion*, **2021**, 58, 72-82	4.9	5
151	Development and internal validation of a prediction model for hospital-acquired acute kidney injury. *CKJ: Clinical Kidney Journal*, **2021**, 14, 309-316	4.5	5
150	Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 432-441	4.5	5
149	Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review.. *Tuberkuloz Ve Toraks*, **2021**, 69, 547-560	0.8	5
148	Peritoneal dialysis and kidney transplant. A two-way ticket in an integrated renal replacement therapy model. *Nefrologia*, **2011**, 31, 441-8	1.5	5
147	Chronodisruption: A Poorly Recognized Feature of CKD. *Toxins*, **2020**, 12,	4.9	4
146	Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
145	Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?. *BMC Nephrology*, **2012**, 13, 21	2.7	4
144	Involvement of lipid mediators in the pathogenesis of experimental nephrosis in rats: its pharmacological modulation. *Renal Failure*, **1991**, 13, 95-101	2.9	4
143	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. *Expert Opinion on Drug Discovery*, **2020**, 15, 101-115	6.2	4
142	Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1879-1885	4.5	4
141	Hypertension in kidney transplantation: a consensus statement of the Hypertension and the kidney working group of the European Society of Hypertension. *Journal of Hypertension*, **2021**, 39, 1513-1521	4.8	4

140	Acute Kidney Injury is Aggravated in Aged Mice by the Exacerbation of Proinflammatory Processes. *Frontiers in Pharmacology*, **2021**, 12, 662020	5.6	4
139	A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size. *Kidney International*, **2021**, 99, 1331-1341	9.9	4
138	Resistant hypertension: new insights and therapeutic perspectives. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2020**, 6, 188-193	6.4	4
137	Podocyte and tubular involvement in AngioJet-induced kidney injury. *CKJ: Clinical Kidney Journal*, **2021**, 14, 424-428	4.5	4
136	Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. *Nephrology Dialysis Transplantation*, **2021**,	4.3	4
135	Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. *Therapeutic Apheresis and Dialysis*, **2021**, 25, 908-916	1.9	4
134	Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole. *CKJ: Clinical Kidney Journal*, **2018**, 11, 688-690	4.5	4
133	Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. *Nephrology Dialysis Transplantation*, **2021**,	4.3	4
132	TWEAK and the kidney: the dual role of a multifunctional cytokine. *Advances in Experimental Medicine and Biology*, **2011**, 691, 323-35	3.6	4
131	Will modulation of cell death increase PD technique survival?. *Peritoneal Dialysis International*, **2004**, 24, 105-14	2.8	4
130	Bcl-xL prevents peritoneal dialysis solution-induced leukocyte apoptosis. *Peritoneal Dialysis International*, **2008**, 28 Suppl 5, S48-52	2.8	4
129	Positive/retained SDHB immunostaining in renal cell carcinomas associated to germline SDHB-deficiency: case report. *Diagnostic Pathology*, **2019**, 14, 42	3	3
128	Burden, access and disparities in kidney disease: chronic kidney disease hotspots and progress one step at a time. *CKJ: Clinical Kidney Journal*, **2019**, 12, 157-159	4.5	3
127	'That Obscure Object of Desire'? in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. *Nephrology Dialysis Transplantation*, **2015**, 30, 394-400	4.3	3
126	Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype. *Molecular Genetics and Metabolism Reports*, **2020**, 25, 100670	1.8	3
125	SGLT2i and postglomerular vasodilation. *Kidney International*, **2020**, 97, 805-806	9.9	3
124	Does wealth make health? Cherchez la renal replacement therapy. *CKJ: Clinical Kidney Journal*, **2017**, 10, 45-48	4.5	3
123	Modifiable risk factors for increased arterial stiffness in outpatient nephrology. *PLoS ONE*, **2015**, 10, e0123903	3.7	3

122	Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. *CKJ: Clinical Kidney Journal*, **2015**, 8, 686-9	4.5	3
121	Identification of a potent endothelium-derived angiogenic factor. *PLoS ONE*, **2013**, 8, e68575	3.7	3
120	Delayed graft function and cotrimoxazole. *Transplantation Proceedings*, **2011**, 43, 2502-4	1.1	3
119	Fabry disease: the many faces of a single disorder. *CKJ: Clinical Kidney Journal*, **2012**, 5, 379-82	4.5	3
118	Cefazolin-induced neurotoxicity. *Clinical Infectious Diseases*, **1992**, 14, 624	11.6	3
117	Persistent anemia after successful kidney graft. *Nephron*, **1991**, 59, 158-9	3.3	3
116	Sarcopenia assessed by 4-step EWGSOP2 in elderly hemodialysis patients: Feasibility and limitations.. *PLoS ONE*, **2022**, 17, e0261459	3.7	3
115	Antifibrotic Agents for the Management of CKD: A Review.. *American Journal of Kidney Diseases*, **2022**,	7.4	3
114	IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis. *Biomolecules*, **2020**, 10,	5.9	3
113	Lyso-Gb3 Increases β3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
112	Phosphate, Microbiota and CKD. *Nutrients*, **2021**, 13,	6.7	3
111	Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**, 16, 1061-1072	6.9	3
110	TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 1913-1932	12.7	3
109	PrEFiNe Plan: Strategic plan for Fabry diseases in Nephrology. *Nefrologia*, **2016**, 36, 376-80	1.5	3
108	MAP3K kinases and kidney injury. *Nefrologia*, **2019**, 39, 568-580	0.4	3
107	Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. *Journal of Nephrology*, **2021**, 34, 39-51	4.8	3
106	Bisphenol S is a haemodialysis-associated xenobiotic that is less toxic than bisphenol A. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1147-1155	4.5	3
105	Suboptimal personal protective equipment and SARS-CoV-2 infection in Nephrologists: a Spanish national survey. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1216-1221	4.5	3

104	Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?. *Nephrology Dialysis Transplantation*, **2021**,	4.3	3
103	Iohexol plasma clearance simplified by Dried Blood Spot (DBS) sampling to measure renal function in conscious mice. *Scientific Reports*, **2021**, 11, 4591	4.9	3
102	Urinary Cyclophilin A as Marker of Tubular Cell Death and Kidney Injury. *Biomedicines*, **2021**, 9,	4.8	3
101	Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium. *Frontiers in Physiology*, **2018**, 9, 1643	4.6	3
100	Cardiovascular Safety of Febuxostat. *New England Journal of Medicine*, **2018**, 379, 1584	59.2	3
99	Evaluation of the impact of an intradialytic exercise programme on sarcopaenia in very elderly haemodialysis patients. *CKJ: Clinical Kidney Journal*,	4.5	3
98	Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 397-406	4.5	3
97	Questioning the Safety of Calcidiol in Hemodialysis Patients. *Nutrients*, **2019**, 11,	6.7	2
96	Proteomics for Clinical Assessment of Kidney Disease. *Proteomics - Clinical Applications*, **2019**, 13, e1900004	3.1	2
95	Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
94	Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography. *International Urology and Nephrology*, **2020**, 52, 541-547	2.3	2
93	Nephrotoxicity **2018**, 169-184		2
92	How should we analyze and present mortality in our patients?: A multicentre GCDP experience. *Nefrologia*, **2016**, 36, 149-55	1.5	2
91	Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants. *Diagnostic Pathology*, **2016**, 11, 2	3	2
90	Machine learning analysis of serum biomarkers for cardiovascular risk assessment in chronic kidney disease. *CKJ: Clinical Kidney Journal*, **2020**, 13, 631-639	4.5	2
89	ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy. *Nature Clinical Practice Nephrology*, **2008**, 4, 472-3		2
88	Taming Apoptosis in Peritoneal Dialysis. *Peritoneal Dialysis International*, **2009**, 29, 45-48	2.8	2
87	The study of apoptosis in spine pathology. *Spine*, **1999**, 24, 500	3.3	2

86	Presence of circulating antibodies against brush border antigens (Fx1A) in a patient with membranous nephropathy and bilateral pyeloureteral stenosis. Comparison with idiopathic membranous nephropathy. *Nephrology Dialysis Transplantation*, **1992**, 7, 293-9	4.3	2
85	Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study.. *Nephrology Dialysis Transplantation*, **2022**,	4.3	2
84	CCN2 (Cellular Communication Network Factor 2) Deletion Alters Vascular Integrity and Function Predisposing to Aneurysm Formation.. *Hypertension*, **2022**, 79, e42-e55	8.5	2
83	[Interleukin-17A: Possible mediator and therapeutic target in hypertension]. *Nefrologia*, **2021**, 41, 244-257	1.5	2
82	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. *Transplant International*, **2021**, 34, 1341-1359	3	2
81	Intravenous iron therapy and the cardiovascular system: risks and benefits. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1067-1076	4.5	2
80	Tasa de ultrafiltraci□ horaria ajustada a peso corporal y mortalidad en hemodi□sis. *Nefrologia*, **2021**, 41, 426-435	1.5	2
79	Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. *Nephrology*, **2021**, 26, 1007-1017	2.2	2
78	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 31-42	4.5	2
77	Brain dysfunction in tubular and tubulointerstitial kidney diseases. *Nephrology Dialysis Transplantation*, **2021**,	4.3	2
76	Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis.. *Kidney International*, **2022**,	9.9	2
75	Start-up of a clinical sample processing, storage and management platform: organisation and development of the REDinREN Biobank. *Nefrologia*, **2012**, 32, 28-34	1.5	2
74	Designing a method to assess and improve the quality of healthcare in Nephrology by means of the Delphi technique. *Nefrologia*, **2014**, 34, 158-74	1.5	2
73	Healthcare-associated infections: new challenges looking for answers. *CKJ: Clinical Kidney Journal*, **2015**, 8, 100-1	4.5	1
72	Reply. *Medicina Cl□nica*, **2017**, 149, 271-272	1	1
71	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered. *Drug Design, Development and Therapy*, **2015**, 9, 5873-4	4.4	1
70	Welcome to the new ckj: an open-access resource integrating clinical, translational and educational research into clinical practice. *CKJ: Clinical Kidney Journal*, **2015**, 8, 1-2	4.5	1
69	Mitochondria-targeted therapies for acute kidney injury □ERRATUM. *Expert Reviews in Molecular Medicine*, **2014**, 16,	6.7	1

68	Apoptosis in the Kidney240-249		1
67	Nephrotoxicity291-310		1
66	Staining for cell death. *Lancet, The*, **2003**, 361, 1748; author reply 1748	40	1
65	Effect of recombinant human growth hormone in a postpediatric hemodialysis patient with delayed growth. *American Journal of Nephrology*, **1992**, 12, 471-3	4.6	1
64	Growth differentiation factor-15 (GDF-15) and syndecan-1 are potential biomarkers of cardiac and renal involvement in classical Fabry disease under enzyme replacement therapy.. *Kidney and Blood Pressure Research*, **2022**,	3.1	1
63	Impact of COVID-19 pandemic in Spanish Nephrology Servicesservices impact of the pandemic on COVID-19 Spanish Nephrology Services. *Nefrologia*, **2020**, 40, 579-584	0.4	1
62	Acute renal failure in patient treated with anti-tumour necrosis factor alpha. *Nefrologia*, **2011**, 31, 484-8	1.5	1
61	Low Intracellular Water, Overhydration, and Mortality in Hemodialysis Patients. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
60	Hematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
59	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. *CKJ: Clinical Kidney Journal*, **2020**, 13, 522-530	4.5	1
58	Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. *Nefrologia*, **2021**, 41, 652-652	1.5	1
57	Interleukin-17A: Potential mediator and therapeutic target in hypertension. *Nefrologia*, **2021**, 41, 244-257	0.4	1
56	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. *Nefrologia*, **2021**, 41, 391-402	1.5	1
55	Working towards novel albuminuria endpoints in chronic kidney disease. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 80-82	18.1	1
54	Undiagnosed cardiovascular risk factors in overweight and obese individuals: a low income country experience. *PeerJ*, **2021**, 9, e10870	3.1	1
53	Estimated GFR Slope in Kidney Transplant Patients: When the Error Is Random. *Transplantation*, **2021**,	1.8	1
52	EDTAKI: A Nephrology and Public Policy Committee (NPPC) Platform Call for More European Involvement in AKI. *Nephrology Dialysis Transplantation*, **2021**,	4.3	1
51	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. *Drugs*, **2021**, 81, 1467-1489	12.1	1

50	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. *Molecular Diagnosis and Therapy*, **2021**, 25, 563-576	4.5	1
49	Aguascalientes: one of the hottest chronic kidney disease (CKD) hotspots in Mexico and a CKD of unknown aetiology mystery to be solved. *CKJ: Clinical Kidney Journal*, **2021**, 14, 2285-2294	4.5	1
48	Primary membranous nephropathy in the era of autoantibodies and biological therapies. *Medicina Clínica*, **2021**, 157, 121-129	1	1
47	Verinurad/Febuxostat and Nephrotoxicity. *American Journal of Kidney Diseases*, **2021**, 78, 468	7.4	1
46	Substitution of Sugar-Sweetened Beverages for Other Beverages: Can It Be the Next Step Towards Healthy Aging?. *Current Nutrition Reports*, **2021**, 1	6	1
45	Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. *International Urology and Nephrology*, **2021**, 53, 1839-1849	2.3	1
44	Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.. *Journal of Nephrology*, **2022**, 1	4.8	1
43	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 865-872	4.5	1
42	First episodes of peritoneal infection: description and prognostic factors. *Nefrologia*, **2013**, 33, 316-24	1.5	1
41	Sarcopenia and Mortality in Older Hemodialysis Patients. *Nutrients*, **2022**, 14, 2354	6.7	1
40	Diagnosis and treatment of Fabry disease. *Medicina Clínica (English Edition)*, **2017**, 148, 132-138	0.3	0
39	The new , 4 years later. *CKJ: Clinical Kidney Journal*, **2019**, 12, 1-5	4.5	0
38	Identification and Chemical Characterization of Insoluble Contaminants in Hemodialysis Water Treatment. *Water (Switzerland)*, **2018**, 10, 486	3	0
37	Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis. *CKJ: Clinical Kidney Journal*, **2013**, 6, 510-2	4.5	0
36	Fatty kidney: A possible future for chronic kidney disease research.. *European Journal of Clinical Investigation*, **2022**, e13748	4.6	0
35	Early glomerular filtration rate changes in living kidney donors and recipients: an example of renal plasticity.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 885-894	4.5	0
34	A sudden decrease in serum creatinine and estimated glomerular filtration rate: clinical implications of administrative gender assignment in transgender persons. *CKJ: Clinical Kidney Journal*, **2020**, 13, 1107-1108	4.5	0
33	TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. *Journal of Pathology*, **2021**, 254, 5-19	9.4	0

32	Use of chronic kidney disease blind spot to prevent cardiorenal outcomes.. *European Heart Journal*, **2022**, 43, 257-260	9.5	0
31	Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1136-1146	4.5	0
30	A primer on metabolic memory: why existing diabesity treatments fail. *CKJ: Clinical Kidney Journal*, **2021**, 14, 756-767	4.5	0
29	The effect of energy restriction on development and progression of chronic kidney disease: review of the current evidence. *British Journal of Nutrition*, **2021**, 125, 1201-1214	3.6	0
28	Nephrology in Spain **2021**, 639-655		0
27	Belimumab in Lupus Nephritis. *New England Journal of Medicine*, **2021**, 384, 187	59.2	0
26	The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease. *Kidney International Reports*, **2021**, 6, 2392-2403	4.1	0
25	Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. *Nefrologia*, **2021**, 41, 652-660	0.4	0
24	Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.. *Drugs*, **2021**, 82, 109	12.1	0
23	The Use of Healthy Eating Index 2015 and Healthy Beverage Index for Predicting and Modifying Cardiovascular and Renal Outcomes.. *Current Nutrition Reports*, **2022**, 1	6	0
22	Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum.. *Clinical Journal of the American Society of Nephrology: CJASN*, **2022**,	6.9	0
21	Spanish multidisciplinary clinical practice guidelines for Anderson□Fabry disease in adults. I. Method and recommendations. *Revista Clínica Espanõla*, **2019**, 219, 200-207	0.5	
20	Persistent acute renal failure in a patient infected with Plasmodium malariae: the importance of renal biopsy. *Nefrologia*, **2020**, 40, 571-573	0.4	
19	CKD **2018**, 319-326		
18	Research update for articles published in EJCI in 2016. *European Journal of Clinical Investigation*, **2018**, 48, e13016	4.6	
17	ERT impact on left ventricular mass in Fabry disease. *Molecular Genetics and Metabolism Reports*, **2019**, 20, 100485	1.8	
16	Resistant Hypertension in Elderly People with Chronic Kidney Disease **2017**, 183-193		
15	The authors reply:. *Kidney International*, **2014**, 85, 1240	9.9	

14	Blood Pressure. *Clinical Therapeutics*, **2012**, 34, e12-e13	3.5
13	Regulation of Vascular and Renal Cells by Common Mediators in Health and Disease: Role of the Renin-Angiotensin System in the Pathophysiology of Hypertension and Cardiovascular Disease **2010**, 49-63	
12	Patogénesis de la malnutrición en pacientes en diálisis con énfasis en los aspectos más específicos de la diálisis peritoneal. *Dialisis Y Trasplante*, **2009**, 30, 57-62	
11	Estrategias en la profilaxis y el tratamiento de la malnutrición en diálisis peritoneal: un problema infradiagnosticado. *Dialisis Y Trasplante*, **2009**, 30, 93-99	
10	Fatal coma and superimposed acute renal failure in a diabetic peritoneal dialysis patient following myelography. *Nephron*, **1992**, 60, 381-2	3.3
9	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. *Nefrologia*, **2021**, 41, 391-402	0.4
8	Reply.. *Journal of Hypertension*, **2022**, 40, 624-626	1.9
7	The renal patient seen by non-renal physicians: the kidney embedded in the "milieu intérieur". *CKJ: Clinical Kidney Journal*, **2021**, 14, 1077-1087	4.5
6	Designing a Method with Physician Participation to Assess and Improve Quality of Healthcare in Otolaryngology. *Journal of International Advanced Otology*, **2017**, 13, 128-135	1.1
5	Sistemas y soluciones de diálisis peritoneal **2009**, 149-164	
4	Increasing serum calcium levels and recent return from transplantation as clues to the tuberculous nature of refractory peritoneal dialysis peritonitis. *Journal of Postgraduate Medicine*, **2014**, 60, 200-1	0.8
3	Kidneys also speak Spanish. *Nefrologia*, **2021**, 41, 224-226	0.4
2	Primary membranous nephropathy in the era of autoantibodies and biological therapies. *Medicina Clínica (English Edition)*, **2021**, 157, 121-129	0.3
1	The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis.. *International Urology and Nephrology*, **2022**, 1	2.3